Clinical Trial Update: RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for rituximab long-term dose in relapsing-remitting multiple sclerosis (RIDOSE-MS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Karolinska Institutet | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: UNKNOWN